Lipocalin 2 acts as a cytoprotective factor against cisplatin toxicity, an in vitro study

Daru

Volumn 16, Issue 2, 2008, Pages 106-111

  Habibi Roudkenar, M ^a   Ghasemipour, Z ^b   Halabian, R ^a   Mohammadi Roushandeh, A ^c   Yaghmai, P ^b   Gharehbaghian, A ^a   Oodi, A ^a   Massrori, N ^a   Amirizadeh, N ^a   Shokrgozar, M A ^d  

^a IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Cisplatin; Cytoprotective factor; Lcn2 NGAL; Toxicity

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DNA ISOLATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 45749110694     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Flower D R, North A C, Sansom C E. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta. 2000; 1482: 9-24.
2. Nilsen-Hamilton M, Hamilton R T, Adams GA. Rapid selective stimulation by growth factors of the incorporation by BALB/C 3T3 cells of [35S] methionine into a glycoprotein and five superinducible proteins. Biochem Biophys Res Commun. 1982; 108: 158-166.
3. Hamilton R T, Nilsen-Hamilton M, Adams G. Superinduction by cycloheximide of mitogen-induced secreted proteins produced by Balb/c 3T3 cells. J Cell Physiol. 1985; 123: 201-208.
4. Kjeldsen, L, Johnsen A H, Sengeløv, H Borregaard N. Isolation of primary structure of Ngal, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993; 268:10425-10432.
5. Cowland J B, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinaseassociated lipocalin from humans. Genomics. 1997; 45: 17-23.
6. Bundgaard J R, Sengelov H, Borregaard N, Kjeldsen L. Molecular cloning and expression of a cDNA encoding Ngal: a lipocalin expressed in human neutrophils. Biochem Biophys Res Commun.1994; 202:1468-1475.
7. Nielsen B S, Borregaard N, Bundgaard J R, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel disease. Gut. 1996; 38: 414-420.
8. Livingston R B. Cisplatin in the treatment of solid tumors: effect of dose and schedule. J. National Cancer Institute. 1989; 81: 724- 725.
9. Kuhlmann M K, Burkhardt G Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant.1997; 12: 2478-2480.
10. Garnick M B, Mayer R J, Abelson H T. Acute renal failure associated with cancer treatment. In: Acute renal failure. Eds.: B. M. Brenner & J. M. Lazarus. Churchill Livingstone, New York. 1988; 621-657.
11. Arany I, Safirstein R L. Cisplatin nephrotoxicity. Semin Nephr.2003; 23: 460-464.
12. Thorsten B, Atsushi T, Gordon S D, Andrew J E, Annick Y T, Andrew W, Hannah E H, Carol CC, Tak WM. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U S A. 2006; 7: 1834-1839.
13. Mishra J, Mori K, Ma Q, Kelly C, Jang J, Mitsnefes M, Barasch J, Devarajan P. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2004; 15: 3073-3082.
14. Roudkenar MH , Bouzari S, Oolomi M, Kuwahara Y, Roushandeh AM, Baba T, Fukumoto M. Assessment of GM-CSF receptors by real - time RT - PCR on various cell lines expressing high and low affinity receptors and their relation to cytotoxic effect of chimeric protein (StxA1-GM-CSF), Daru, 2007, 15:151-155.
15. Stoesz S P, Friedl A, Haag J D, Lindstrom M J, Clark G M, Gould M N. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer.1998; 79: 565-572.
16. Furutani M, Arii S, Mizumoto M, Kato M, Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett.1998; 122: 209-214.
17. Friedl A, Stoesz S P, Buckley P, Gould M N. Neutrophil gelatinaseassociated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 1999; 31:433-441.
18. Yan L, Borregaard N, Kjeldsen L, Moses M A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem.2001; 276: 37258-37265.
19. Cowland J B, Sorensen O E, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-' alpha. J Immunol. 2003; 171: 6630-6639.
20. Roudkenar M H, Kuwahara Y, Baba T, Roushandeh A M, Ebishima S H, Abe S H. Okubo Y Fukumoto M. Oxidative stress induced Lipocalin 2 gene expression, addressing its expression under the harmful condition. J Radiat Res. 2007; 48: 39-44.
21. Tsutsumishita Y, Onda T, Okada K, Takeda M, Endou H, Futaki S, Niwa M. Involvement of H2O2 Production in Cisplatin-Induced Nephrotoxicity. Biochem Biophys Res Comm. 1998; 242: 310-312.
22. Kruidering M, Van de water B, De heer E, Erard JM, Fred nagelkerke J. Cisplatin-Induced Nephrotoxicity in Porcine Proximal Tubular Cells: Mitochondrial Dysfunction by Inhibition of Complexes I to IV of the Respiratory Chain. JPET. 1997; 280: 638-649.
23. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen C S, Kehrer J P. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J.2005; 391: 441-448.
24. Hung Y C, Huang G S, Lin L W, Hong M Y, Theasinensis P S. Melanin prevents cisplatin-induced nephrotoxicity in mice. Food and Chemical Toxicology. 2007; 45: 1123-1130.